Free Trial

Manufacturing Stocks List

This page shows information about the 50 largest manufacturing sector stocks including Inphi, Kadmon, Cantaloupe, and CoreCard. Learn more about manufacturing stocks.

Inphi logo

#1 - Inphi

NYSE:IPHI - See Stock Forecast
Stock Price:
$172.27
Market Cap:
$9.25 billion
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Kadmon logo

#2 - Kadmon

NYSE:KDMN - See Stock Forecast
Stock Price:
$9.50
Market Cap:
$1.70 billion
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Kadmon is a clinical-stage biopharmaceutical company that discovers, develops and delivers transformative therapies for unmet medical needs. Its clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies.
Cantaloupe logo

#3 - Cantaloupe

NASDAQ:USAT - See Stock Forecast
Stock Price:
$9.58 (+$0.27)
Market Cap:
$680.94 million
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Cantaloupe, Inc. is a software and payments company, which engages in the provision of end-to-end technology solutions for the unattended retail market. It offers Internet of Things (IoT) and machine-to-machine (M2M) services, which include the ability to remotely monitor, control, and report on the results of distributed assets containing the electronic payment solutions. The company was founded by George Raymond Jensen Jr. in January 1992 and is headquartered in Malvern, PA.
CoreCard logo

#4 - CoreCard

NYSE:INS - See Stock Forecast
Stock Price:
$0.00
Market Cap:
$349.35 million
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
CoreCard Corp. engages in the management of emerging technology companies. It operates through CoreCard Software, Inc. and affiliate companies, which are involved in the design, development, and marketing of software solutions to corporations, financial institutions, retailers, and processors to manage credit and debit cards, prepaid cards, private label cards, fleet cards, loyalty programs, and accounts receivable and small loan transactions. The company was founded in 1973 and is headquartered in Norcross, GA.
CRH Medical logo

#5 - CRH Medical

NYSE:CRHM - See Stock Forecast
Stock Price:
$3.99
Market Cap:
$285.76 million
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
IEC Electronics logo

#6 - IEC Electronics

NYSE:IEC - See Stock Forecast
Stock Price:
$15.34
Market Cap:
$162.97 million
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
IEC Electronics is a provider of electronic manufacturing services ('EMS') to advanced technology companies that produce life-saving and mission critical products for the medical, industrial, and aerospace and defense sectors. The Company specializes in delivering technical solutions for the custom manufacture of complex full system assemblies by providing on-site analytical testing laboratories, custom design and test engineering services combined with a broad array of manufacturing services encompassing electronics, interconnect solutions, and precision metalworking. As a full service EMS provider, IEC holds all appropriate certifications for the market sectors it supports including ISO 9001:2015, AS9100D, ISO 13485, and is Nadcap accredited. IEC Electronics is headquartered in Newark, NY and also has operations in Rochester, NY and Albuquerque, NM.
Did You See Trump’s Bombshell Exec. Order 001? (Ad)

Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."

I put all the details together for you here — but please hurry. 
FBR & Co. logo

#7 - FBR & Co.

NASDAQ:FBRC - See Stock Forecast
Stock Price:
$17.55
Market Cap:
$124.61 million
Dividend Yield:
4.52%
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
FBR & Co. is an investment banking and institutional brokerage company. The Company focuses on the equity capital markets. The Company operates through two segments: capital markets, which includes investment banking, institutional brokerage and research, and principal investing. Through its broker-dealer operating subsidiaries, the Company focuses its business on providing: capital raising services, including underwriting and placement of public and private equity, equity-linked and debt securities; financial advisory services, including merger and acquisition (M&A) advisory, restructuring, liability management, recapitalization and strategic alternative analysis; institutional sales and trading services focused on equities, equity-linked securities, listed options, high-yield bonds, senior debt and bank loans, as well as securities lending activities, and differentiated securities research.

#8 - Orbital Energy Group

NASDAQ:OEG - See Stock Forecast
Stock Price:
$0.00
Market Cap:
$55.87 million
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Orbital Infrastructure Group, Inc. engages in the acquisition, development and commercialization of electro-mechanical products and technologies worldwide. It operates through the following segments: Electric Power, Telecommunications and Renewables. The Electric Power segment provides comprehensive infrastructure solutions to customers in the electric power industry. The Telecommunications segment provides enterprise solutions to the cable and telecommunication industries. The Renewables segment focuses on utility-scale solar construction. The company was founded on April 21, 1998 and is headquartered in Houston, TX.
Tailwind Two Acquisition logo

#9 - Tailwind Two Acquisition

NYSE:TWNT - See Stock Forecast
Stock Price:
$0.00
Market Cap:
$10.78 million
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Tailwind Two Acquisition Corp. focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or other business combination with one or more businesses or entities. The company was incorporated in 2020 and is based in New York, New York.
LadRx logo

#10 - LadRx

NASDAQ:CYTR - See Stock Forecast
Stock Price:
$0.00
Market Cap:
$4.14 million
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
LadRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. It focuses on developing the Linker Activated Drug Release (LADR) technology platform, a discovery engine to help create a pipeline of anti-cancer molecules that will avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor. The company was founded in 1985 and is headquartered in Los Angeles, CA.

#11 - TradeUP Acquisition

NASDAQ:UPTDW - See Stock Forecast
Stock Price:
$0.09 (+$0.00)
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.
Exchange Income logo

#12 - Exchange Income

NYSE:EIF - See Stock Forecast
Stock Price:
$0.00
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Jupiter Wellness logo

#13 - Jupiter Wellness

NASDAQ:JUPWW - See Stock Forecast
Stock Price:
$0.19 (-$0.00)
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
jupiter wellness, inc. operates as a hemp-derived cannabidiol (cbd) consumer product development company. it develops various therapeutic and medical use for cbd in the treatment of various ailment and diseases, such as cancer, arthritis, anxiety, insomnia, psoriasis, chronic pain, and others. the company markets cbd-infused sun care lotion formulas containing various sun protection factors under the canisun brand. it is also developing other products, such as cbd-infused skin care lotion under the caniskin brand; and dermatological treatments under the canidermrx brand. the company was formerly known as cbd brands, inc. jupiter wellness, inc. was founded in 2018 and is headquartered in jupiter, florida.
Electric Last Mile Solutions, I logo

#14 - Electric Last Mile Solutions, I

NASDAQ:ELMSW - See Stock Forecast
Stock Price:
$0.00
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Electric Last Mile Solutions, Inc., a commercial electric vehicle solutions company, focuses on designing, engineering, manufacturing, and customizing electric ‘last mile' delivery and utility vehicles. It offers Class 1 commercial electric vehicle in the U.S. market and focuses on producing Class 3 Urban Utility electric vehicle. The company is headquartered in Troy, Michigan.
Velodyne Lidar logo

#15 - Velodyne Lidar

NASDAQ:VLDRW - See Stock Forecast
Stock Price:
$0.32
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Entera Bio Ltd. WT EXP 062723 logo

#16 - Entera Bio Ltd. WT EXP 062723

NASDAQ:ENTXW - See Stock Forecast
Stock Price:
$0.00
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Welsbach Technology Metals Acquisition logo

#17 - Welsbach Technology Metals Acquisition

NASDAQ:WTMAR - See Stock Forecast
Stock Price:
$0.10
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Welsbach Technology Metals Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It intends to focus on the technology metals and energy transition metals sectors. Welsbach Technology Metals Acquisition Corp. was incorporated in 2021 and is based in Lombard, Illinois.
Second Sight Medical Products logo

#18 - Second Sight Medical Products

NASDAQ:EYESW - See Stock Forecast
Stock Price:
$0.02
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A

#19 - Zhengye Biotechnology

NASDAQ:ZYBT - See Stock Forecast
Stock Price:
$0.00
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Zhengye Biotechnology Holding Limited is a manufacturing company in the Pharmaceutical Products industry.

#20 - FBS Global

NASDAQ:FBGL - See Stock Forecast
Stock Price:
$0.00
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
FBS Global Ltd. is a manufacturing company in the Misc. industry.

#21 - Psyence Biomedical

NASDAQ:PBMWW - See Stock Forecast
Stock Price:
$0.02 (+$0.00)
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Psyence Biomedical Ltd. is a manufacturing company in the Pharmaceutical Products industry.

#22 - Fidelity Select Wireless

NASDAQ:FWRLX - See Stock Forecast
Stock Price:
$13.12 (-$0.01)
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A

#23 - Parex Resources

NYSE:PXT - See Stock Forecast
Stock Price:
$0.00
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A

#24 - G Medical Innovations

NASDAQ:GMVDW - See Stock Forecast
Stock Price:
$0.00
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
G Medical Innovations Holdings Ltd, together with its subsidiaries, an early commercial stage healthcare company, engages in the development of next generation mobile health and telemedicine solutions in the United States, China, and Israel. The company's products include Prizma, a plug-and-play medical device that measures vital signs with electronic medical records functionality and clinical grade reporting standards; and Extended Holter Patch System, a multi-channel patient-worn biosensor that captures electrocardiogram data continuously for up to 14 days. It also develops Wireless Vital Signs Monitoring System, a solution that provides continuous real time monitoring of vital signs and biometrics. In addition, it offers monitoring services, including independent diagnostic testing facility monitoring and private monitoring services. The company was incorporated in 2014 and is based in Rehovot, Israel.

#25 - Rosecliff Acquisition Corp I

NASDAQ:RCLFW - See Stock Forecast
Stock Price:
$0.47 (+$0.05)
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Spectral AI, Inc. operates as an artificial intelligence (AI) company. The company focuses on medical diagnostics for faster and accurate treatment decisions in wound care with applications involving patients with burns and diabetic foot ulcers. Its products include DeepView, a predictive diagnostic device that offers clinicians an objective and immediate assessment of a wound's healing potential prior to treatment or other medical intervention. The company is based in Dallas, Texas.
Immuron logo

#26 - Immuron

NASDAQ:IMRNW - See Stock Forecast
Stock Price:
$0.07
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A

#27 - Electrameccanica Vehicles Corp. WT EXP 080323

NASDAQ:SOLOW - See Stock Forecast
Stock Price:
$0.01 (-$0.00)
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
more than 83% of canadian commuters drive alone in vehicles not ideally suited for this purpose. this results in roadway congestion, higher fuel costs, and increased air pollution. electra meccanica's solo is the ideal commuter car that fits perfectly into your busy lifestyle being both good for you and the planet. designed by a world-class development team, it's modern aesthetics are matched by spirited performance and ultimate practicality. for more information about the solo, purchasing, investing, dealerships or scheduling a test drive, please get in touch at info@electrameccanica.com or by giving us a call at 1-604-428-7656 reserve yours now for only $250cad http://electrameccanica.com/reserve/ facebook: electrameccanica twitter: @electramecc instagram: electrameccanica
indie Semiconductor logo

#28 - indie Semiconductor

NASDAQ:INDIW - See Stock Forecast
Stock Price:
$1.26 (-$0.04)
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
indie designs and manufactures custom, microcontroller-based chips, using arm cores. we replace most of the contents of a printed circuit board with a single, optimal chip designed specifically for your application. this reduces the product cost, size and power compared with solutions based around standard, off-the-shelf components. reliability, manufacturability and security are all increased. aside from its skills in mixed signal design, indie's strengths are the way we can stitch new designs together quickly and cheaply, allowing applications to get the benefits of system-on-chip technology without the normal downsides. we have multiple designs in production and ship volumes of million-plus units per month and are growing fast.
Palladyne AI logo

#29 - Palladyne AI

NASDAQ:STRCW - See Stock Forecast
Stock Price:
$0.17 (-$0.01)
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Palladyne AI Corp., a software company, focuses on delivering software that enhances the utility and functionality of third-party stationary and mobile robotic systems in the United States. Its Artificial Intelligence (AI)/ Machine Learning (ML) software platform enables robots to observe, learn, reason, and act in structured and unstructured environments. The company's software platform enables robotic systems to perceive their environment and quickly adapt to changing circumstances by generalizing from their experience using dynamic real-time operations without extensive programming and with minimal robot training. It serves customers from various industries, such as industrial manufacturing, warehousing and logistics, defense, infrastructure maintenance and repair, energy, aerospace and aviation, and others. The company was formerly known as Sarcos Technology and Robotics Corporation and changed its name to Palladyne AI Corp. in March 2024. Palladyne AI Corp. was founded in 2017 and is headquartered in Salt Lake City, Utah.

#30 - ACE Convergence Acquisition

NASDAQ:ACEVW - See Stock Forecast
Stock Price:
$0.00
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A

#31 - BioLingus (Cayman)

NASDAQ:SUBL - See Stock Forecast
Stock Price:
$0.00
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
We are an exempted company with limited liability incorporated under the laws of the Cayman Islands, which is structured as a holding company whose main business operations are conducted through our subsidiaries in Switzerland and to a lesser extent, HK SAR, the People's Republic of China and Australia. We are a biotechnology company spearheading the development of oral (specifically, sublingual) delivery of peptides and proteins. Many of the more effective drugs to treat diabetes and obesity are “biologics”, the vast majority of which currently have to be injected. For example, although insulin was discovered almost 100 years ago, there has, to date, not been any commercially viable solution to administer insulin without the need for injection. Consistent with this, the delivery of peptides or proteins, such as insulin, in a non-invasive way (i.e. without needles or injections) is a very challenging endeavor from a scientific and technical perspective. Since our inception, we have focused on developing an alternative approach, known as sublingual delivery. The sublingual area lies under the tongue and is lined by a thin layer of cells which has a rich supply of blood vessels. Sublingual delivery has been successfully used commercially for many years to deliver a variety of so-called small molecule drugs, such as glyceryl trinitrate and ondansetron, which can readily penetrate this layer of cells to rapidly enter the blood stream. We hypothesized that we could similarly exploit the unique nature of the sublingual area to effectively deliver peptides and proteins, and this subsequently became the focus of our research. The main peptide used to improve the technology was exenatide, which was the first commercial glucagon-like peptide (GLP-1) receptor protein product and is routinely used to treat type 2 diabetes. During our first series of studies with exenatide, the sublingual dose required was almost 200 times the injectable dose to achieve a similar effect. After 2 to 3 years of extensive development, we were able to reduce this ratio to 5 to 10, and we now have a “platform” of formulations (the “BioLingus Platform”) and expertise on how formulations should be designed for better performance. During the course of our research and testing of various peptides and proteins across several different disease indications, it has become clear to us that there are two areas for our technology with significant commercial potential: . Metabolic disease, in particular diabetes and obesity and related metabolic disorders such as nonalcoholic steatohepatitis (“NASH”); and . Immunology (mainly allergy and auto-immune disorders)(1). (1) A perpetual and irrevocable license has been granted to all non-metabolic applications from BioLingus IP GmbH to BioLingus IP II GmbH. BioLingus IP GmbH only holds the rights to the metabolic applications. In 2019, BioLingus IP II GmbH was spun-out of BioLingus IP GmbH and we no longer own BioLingus IP II GmbH. Our principal executive office is located at Grossmatt 6, CH-6052 Hergiswil NW, Switzerland. Our registered offices in the Cayman Islands are located at Ogier Global (Cayman) Limited, 89 Nexus Way, Camana Bay, Grand Cayman, KY1-9009, Cayman Islands.

#32 - Adial Pharmaceuticals, Inc. WT EXP 073123

NASDAQ:ADILW - See Stock Forecast
Stock Price:
$0.00 (-$0.00)
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
adial pharmaceuticals is dedicated to personalized treatment for drug abuse and addiction. while our pipeline includes drug candidates for the treatment of opiate and amphetamine use, our two lead drug candidates are for the treatment of alcohol abuse. adial leverages its extensive knowledge of pharmacology and pharmacogenomics to change the paradigm of drug abuse treatment.

#33 - Switchback II

NYSE:SWBKU - See Stock Forecast
Stock Price:
$0.00
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A

#34 - Aesther Healthcare Acquisition

NASDAQ:AEHAW - See Stock Forecast
Stock Price:
$0.04 (-$0.00)
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Aesther Healthcare Acquisition Corp. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in New York, New York.
Stanley Black & Decker logo

#35 - Stanley Black & Decker

NYSE:SWT - See Stock Forecast
Stock Price:
$51.06 (-$1.51)
Dividend Yield:
4.75%
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Anzu Special Acquisition Corp I logo

#36 - Anzu Special Acquisition Corp I

NASDAQ:ANZUW - See Stock Forecast
Stock Price:
$0.05
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Envoy Medical, Inc., a hearing health company, provides medical technologies for the hearing loss spectrum. Its products include hearing aids; Esteem middle ear implants; bone conduction devices, such as auditory osseointegrated implants; and Acclaim cochlear implants. The company was formerly known as Envoy Medical Corporation and changed its name to Envoy Medical, Inc. in September 2023. Envoy Medical, Inc. was founded in 1995 and is headquartered in White Bear Lake, Minnesota.
ToughBuilt Industries, Inc. WT EXP 110923 logo

#37 - ToughBuilt Industries, Inc. WT EXP 110923

NASDAQ:TBLTW - See Stock Forecast
Stock Price:
$0.01 (+$0.00)
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
ToughBuilt Industries Inc. is an advanced product design, manufacturer and distributor with emphasis on innovative products. Currently focused on tools and other accessories for the professional and do-it-yourself construction industries. The Company markets and distributes various home improvement and construction product lines for both the do-it-yourself and professional markets under the TOUGHBUILT brand name, within the global multibillion dollar per year tool market industry. All of its products are designed by its in-house design team. Since launching product sales in 2013, the company has experienced significant annual sales growth. Its current product line includes three major categories, with several additional categories in various stages of development, consisting of Soft Goods & Kneepads and Sawhorses & Work Products. Its mission is to provide products to the building and home improvement communities that are innovative, of superior quality derived in part from enlightened creativity for its end users while enhancing performance, improving well-being and building high brand loyalty.

#38 - Apollo Strategic Growth Capital II Units

NASDAQ:APGBU - See Stock Forecast
Stock Price:
$10.66
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Apollo Strategic Growth Capital II intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was formerly known as APH I (Sub I), Ltd. and changed its name to Apollo Strategic Growth Capital II in December 2020. Apollo Strategic Growth Capital II was incorporated in 2008 and is based in New York, New York.

#39 - 4D pharma

NASDAQ:LBPSW - See Stock Forecast
Stock Price:
$0.00
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
4D pharma plc, together with its subsidiaries, engages in the research, development, and production of live biotherapeutic products. The company develops therapeutic candidates, such as MRx0518; MRx-4DP000 for the treatment of asthma and COVID-19; MRx0029 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, including MRx1299 for solid tumors, MRx0005 for neurodegeneration, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. The company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda and MRx0518 in patients with solid tumors. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom.

#40 - Ascent Solar Technologies

NASDAQ:ASTIW - See Stock Forecast
Stock Price:
$0.00
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Did You See Trump’s Bombshell Exec. Order 001? (Ad)

Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."

I put all the details together for you here — but please hurry. 

#41 - MainstreamBPO

NYSE:MAI - See Stock Forecast
Stock Price:
$0.00
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A

#42 - Biotech Acquisition

NASDAQ:BIOTW - See Stock Forecast
Stock Price:
$0.01 (-$0.07)
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Medigus Ltd. WT C EXP 072323 logo

#43 - Medigus Ltd. WT C EXP 072323

NASDAQ:MDGSW - See Stock Forecast
Stock Price:
$0.02 (-$0.01)
Dividend Yield:
17.24%
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Medigus is a medical device company specializing in developing minimally invasive endosurgical tools and highly innovative imaging solutions across medical and industrial applications.
biote logo

#44 - biote

NASDAQ:BTMDW - See Stock Forecast
Stock Price:
$0.47 (-$0.01)
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
biote Corp. operates in medical practice-building business within the hormone optimization space. The company offers a platform for Biote-certified practitioners to optimize imbalances in their patient's hormone, vitamin, and mineral levels, as well as prescribe bioidentical hormone therapies and recommend dietary supplements. It also sells Biote-branded dietary supplements; and sterile pellet insertion kits for men and women. The company was founded in 2011 and is headquartered in Irvine, Texas.

#45 - Mercury Ecommerce Acquisition

NASDAQ:MEACW - See Stock Forecast
Stock Price:
$0.00
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Mercury Ecommerce Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses. The company was incorporated in 2021 and is based in Houston, Texas.

#46 - Captivision

NASDAQ:CAPTW - See Stock Forecast
Stock Price:
$0.01 (+$0.00)
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Captivision Inc. is a manufacturing company in the Electrical Equipment industry.

#47 - Majestic Ideal

NASDAQ:MJID - See Stock Forecast
Stock Price:
$0.00
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
We are a holding company incorporated in the Cayman Islands with operations conducted by our PRC subsidiary New Brand, which is headquartered in Shanghai, the PRC. We are a provider of SCM services in the apparel industry delivering a one-stop solution to our customers for a broad range of yarn products, textiles and finished garments. Our service offerings encompass every key aspect of the supply chain of these products: market trend analysis, product design and development, raw material sourcing, production and quality control, and logistics management. Through our integrated capabilities, we provide end-to-end supply chain solutions that are tailored to meet our customers' unique needs. Our principal offices are located at 22/F, China United Plaza, 1002-1008 Tai Nan West Street, Cheung Sha Wan, Kowloon, Hong Kong. Our registered office in the Cayman Islands is located at the Conyers Trust Company (Cayman) Limited, Cricket Square, Hutchins Drive, PO Box 2681, Grand Cayman, KY1-1111, Cayman Islands. Our agent for service of process in the United States is Cogency Global Inc., located at 122 East 42nd Street, 18th Floor New York, NY.
Chase logo

#48 - Chase

NYSE:CCF - See Stock Forecast
Stock Price:
$127.49
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Chase Corporation, a specialty chemicals company, manufactures and sells protective materials for various applications worldwide. It operates through three segments: Adhesives, Sealants and Additives; Industrial Tapes; and Corrosion Protection and Waterproofing. The Adhesives, Sealants and Additives segment offers protective conformal and moisture protective electronic coatings and cleaning solutions; advanced adhesives, sealants, and coatings; polymeric microspheres; polyurethane dispersions; superabsorbent polymers; and cleaning and protection solutions for electronic assemblies. The Industrial Tapes segment provides wire and cable materials; specialty tapes and related products; insulating and conducting materials; laminated durable papers; water-blocking compounds; laminated film foils and cover tapes; and pulling and detection tapes. The Corrosion Protection and Waterproofing segment offers protective pipe-coating tapes and other protectants; polymeric asphalt additives; waterproofing membranes; waterproofing sealants, expansion joints, and accessories; technological products, and tapes and membranes; specialized high-performance coating and lining systems; waterproofing and corrosion protection systems; and pipeline protection tapes and products. It sells its products through its salespeople, as well as manufacturers' representatives and distributors. The company was founded in 1946 and is headquartered in Westwood, Massachusetts.
ENDRA Life Sciences logo

#49 - ENDRA Life Sciences

NASDAQ:NDRAW - See Stock Forecast
Stock Price:
$0.03
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Chase logo

#50 - Chase

NYSE:CCF - See Stock Forecast
Stock Price:
$127.49
Consensus Rating:
N/A (0 Strong Buy Ratings, 0 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Chase Corporation, a specialty chemicals company, manufactures and sells protective materials for various applications worldwide. It operates through three segments: Adhesives, Sealants and Additives; Industrial Tapes; and Corrosion Protection and Waterproofing. The Adhesives, Sealants and Additives segment offers protective conformal and moisture protective electronic coatings and cleaning solutions; advanced adhesives, sealants, and coatings; polymeric microspheres; polyurethane dispersions; superabsorbent polymers; and cleaning and protection solutions for electronic assemblies. The Industrial Tapes segment provides wire and cable materials; specialty tapes and related products; insulating and conducting materials; laminated durable papers; water-blocking compounds; laminated film foils and cover tapes; and pulling and detection tapes. The Corrosion Protection and Waterproofing segment offers protective pipe-coating tapes and other protectants; polymeric asphalt additives; waterproofing membranes; waterproofing sealants, expansion joints, and accessories; technological products, and tapes and membranes; specialized high-performance coating and lining systems; waterproofing and corrosion protection systems; and pipeline protection tapes and products. It sells its products through its salespeople, as well as manufacturers' representatives and distributors. The company was founded in 1946 and is headquartered in Westwood, Massachusetts.

(Ad)

Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."

More Stock Ideas from MarketBeat